Less surgery may be enough for rare pancreatic tumor, study suggests
NCT ID NCT07592663
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 708 patients with a rare, low-grade pancreatic tumor called solid pseudopapillary neoplasm. Researchers compared a less invasive surgery that saves healthy pancreas tissue to a more extensive surgery that removes more of the organ. They also examined whether removing nearby lymph nodes is necessary. The goal was to see if the less invasive approach is safe and effective over the long term.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Parenchyma-sparing resection (a less invasive surgery that removes the tumor while saving as much healthy pancreas as possible)
- What this could lead to
- If successful, this could show that less invasive surgery is safe for this rare tumor and that removing lymph nodes may not be necessary, helping patients recover faster with fewer long-term side effects.
- What could go wrong
- This is a completed observational study, not a randomized trial, so results may not apply to all patients. The tumor is low-grade, so the benefits of less surgery may not be as clear for more aggressive cancers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
708 people
The number who actually took part.
- Started
-
Jul 2008
- Finished
-
Mar 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients were eligible if they underwent surgical resection for pathologically confirmed SPN at the study center.
- Ages
-
14 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. age between 18 and 75 years, regardless of gender; 2. patients with solid pseudopapillary neoplasm of the pancreas; 3. patients with an ECOG performance status of 0 or 1; 4. successfully received sugary (open or laparoscopic or robotic) Exclusion Criteria: (1) Pediatric patients with SPN under 14 years of age, or elderly patients over 80 years of age; (2) Reoperative resection for recurrent or metastatic SPN; (3) presence of distant metastasis or concomitant malignant tumors before surgery; and (4) loss to follow-up within 90 days after surgery.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pancreatic tumor, benign are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.